Fundraising Fox
/Companies
Sign in

AgeneBio

Baltimore, US · Delaware corporation

Find your way into AgeneBio

Sign up to see every warm intro you have to AgeneBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AgeneBio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AgeneBio is a clinical-stage biopharmaceutical company developing therapeutics for patients at risk of neurological and psychiatric conditions. Its lead late-stage clinical program targets the prevention of Alzheimer's dementia.

BiotechDigital Health

Founders & leadership

MGMICHELA GALLAGHER
MICHELA GALLAGHERFounder
SRSHARON ROSENZWEIG-LIPSON
SHARON ROSENZWEIG-LIPSONVice President of Research and Development2011–2024Executive Officer at Life Biosciences
GW
GERALD W. MCLAUGHLINExecutive

Board

RN
RONALD NORDMANNBoard director
CC
CHARLES CLARVITBoard director
PL
PATRICK LEPOREBoard director
FB
FLOYD BLOOMBoard director

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 3 rounds · 2014–2016

▶$500.1KraisedJul 2016 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • FLOYD BLOOMDirector
  • CHARLES CLARVITDirector
  • RONALD NORDMANNDirector
  • PATRICK LEPOREDirector
  • MICHELA GALLAGHERDirector
  • GERALD W. MCLAUGHLINExecutive Officer, Director
Offering amount
$3M
Amount sold
$500.1K
First sale
Jul 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$400KraisedFeb 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • RONALD NORDMANNDirector
  • CHARLES CLARVITDirector
  • PATRICK LEPOREDirector
  • SHARON ROSENZWEIG-LIPSONExecutive Officer
  • GERALD W. MCLAUGHLINExecutive Officer, Director
  • FLOYD BLOOMDirector
  • MICHELA GALLAGHERExecutive Officer, Director
Offering amount
$900K
Amount sold
$400K
First sale
Jan 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedOct 2014 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • PATRICK LEPOREDirector
  • GERALD W. MCLAUGHLINExecutive Officer, Director
  • FLOYD BLOOMDirector
  • SHARON ROSENZWEIG-LIPSONExecutive Officer
  • RONALD NORDMANNDirector
  • CHARLES CLARVITDirector
  • MICHELA GALLAGHERExecutive Officer, Director
Offering amount
$10M
Amount sold
$4.1M
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Sanegene BioSanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Catena BiosciencesCatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.
IndieBioIndieBio was a startup accelerator and pre-seed investment program launched by SOSV in San Francisco in 2015, providing on-site bio-labs and funding to science founders across biotech, food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics. As of 2026 the program was rebranded to SOSV NY and SOSV SF, expanding its focus from bio to broader deep tech.

Companies working in the same space as AgeneBio.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$1.1M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

AgeneBio Announces Additional Funding to Advance GABA-A Therapeutic Program : AgeneBioagenebio.com · Sep 2019AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer's Diseaseprnewswire.com · Sep 2017Neurological Degenerative Therapeutic Research Investment & Funding Relations | AgeneBio : AgeneBioagenebio.com · Dec 2014

Frequently asked questions

What does AgeneBio do?
AgeneBio is a clinical-stage biopharmaceutical company developing therapeutics for patients at risk of neurological and psychiatric conditions. Its lead late-stage clinical program targets the prevention of Alzheimer's dementia.
Who founded AgeneBio?
AgeneBio was founded by MICHELA GALLAGHER.
How much funding has AgeneBio raised?
AgeneBio has disclosed $5M raised across 3 rounds.
Where is AgeneBio headquartered?
AgeneBio is headquartered in Baltimore, US.